期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

儿童复发难治性急性白血病分子靶向治疗进展 被引量：3

下载PDF
导出
摘要 儿童急性白血病（acute leukemia,AL）出现复发或难治,其长期存活机会极少,传统化疗可使急性淋巴细胞白血病（acute lymphoblastic leukemia,ALL）患儿完全缓解率达81.0%～93.0%[1-2],但长期无病生存率只有27.0%～50.0%[2-3]。早期骨髓复发及T细胞急性淋巴细胞白血病（T-cell acute lymphoblastic leukemia,T-ALL）复发者预后更差，5年生存率只有20．0％.
作者 邱国胜 于洁
机构地区 重庆医科大学附属儿童医院
出处 《现代医药卫生》 2015年第17期2604-2607,共4页 Journal of Modern Medicine & Health
关键词 白血病/治疗 白血病 淋巴样/治疗 急性病 儿童 综述
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Ko RH, Ji L,Bamette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia:a Therapeutic Advances in Child- hoed Leukemia Consortium study[J]. J Clin Oncol,2010,28(4) :648-654.
  • 2Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course muhidrug chemotherapy:results of trial ALL-REZ BFM 90[j]. J Clin Oneol,2010,28 (14):2339-2347.
  • 3Raetz EA,Borowitz MJ,Devidas M ,et al. Reinduetion platform for children with first marrow relapse of acute lyrnphoblastic Leukemia:A Children's Oneology Group Study[corrected[J]. J Clin Oneol, 2008,26 (24) : 3971-3978.
  • 4Orlowski RJ ,Mangan JK ,Luger SM. Approach to patients with primary refractory acute myeloid leukemia [J]. Curr Opin Hematol, 2015,22 (2) : 97-107.
  • 5Gorman MF, Ji L, Ko RH,et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML):a Therapeutic Advances in Childhood Leukemia(TACL) Consortium study[J]. Pediatr Blood Cancer, 2010,55(3) :421-429.
  • 6萧杏贤,尹松梅.成人急性淋巴细胞白血病单克隆抗体治疗的研究进展[J].国际医药卫生导报,2013,19(11):1721-1722. 被引量：4
  • 7王潇苓.利妥昔单抗治疗血液系统恶性肿瘤的临床疗效研究[J].吉林医学,2014,35(31):6897-6899. 被引量：3
  • 8Thomas DA,O'Brien S, Faderl S,et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia[J]. J Clin Oncol, 2010,28 (24) : 3880-3889.
  • 9Meinhardt A ,Burkhardt B ,Zimmermann M ,et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin' s lymphoma and Burkitt leukemia[J]. J Clin Oncol,2010,28 (19) :3115-3121.
  • 10Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse:a Children's Oncology Group Pilot Study[J]. J Clin Oncol, 2008, 26 (22) : 3756-3762.

二级参考文献31

  • 1王玉刚,沈倍奋.CD20抗原及治疗性抗CD20抗体[J].中国肿瘤生物治疗杂志,2005,12(1):76-79. 被引量：10
  • 2屈浩 ,廖晓龙 .CD52抗原的研究进展及其抗体在临床中的应用[J].国外医学（免疫学分册）,2005,28(6):369-373. 被引量：3
  • 3Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia[J]. Blood, 2009, 113(25): 6330-6337.
  • 4Maury S, Huguet F, Leguay T, et al.Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia [J].Haematologica, 95(2): 324-328.
  • 5Bachanova V, Sandhu K, Yohe S, et al. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia[J]. Blood, 2011, 117(19): 5261-5263.
  • 6Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphobtastic leukemia[J].Cancer, 2006, 106(7): 1569-1580.
  • 7Thomas DA, O' Brien S, Cortes JE, et al.Long-term outcome for de novo or minimally treated Burkitt-type lymphoma/leukemia(BL/B-ALL)after therapy with Hyper- CVAD and rituximab[J].ASH Annual Meeting Abstracts, 2010, 116: 1781.
  • 8Deborah A Thomas, Susan O'Brien, Stefan Faderl, et al.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-Lineage acutelymphoblastic leukemia[J].J Clin Oncol, 2010, 28(24): 3880-3889.
  • 9Hoelzer D, Huettmann A, Kaul F, et al.lmmunochemotherapy with rituximab improves molecular CR rate and outcome In CD20+B-lineage standard and high risk patients, results of 263 CD20+patients studied prospectively in GMALL study 07/2003[J].ASH Annual Meeting Abstracts, 2010, 116: 170.
  • 10Chevallier P, Pigneux A, Robillard N, et al.Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series[J]. Leukemia Research, 2012, 36(3): 311-315.

共引文献5

同被引文献21

引证文献3

二级引证文献17

现代医药卫生
2015年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部